Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.

导出 LinkOut

翻译打印收藏纠错

作者： Taizo,Uchimoto ^[1] ; Tatsuo,Fukushima ^[1] ; Kazumasa,Komura ^[1] ; Wataru,Fukuokaya ^[2] ; Takahiro,Adachi ^[3] ; Takeshi,Hashimoto ^[3] ; Atsuhiko,Yoshizawa ^[4] ; Ko,Nakamura ^[1] ; Yusuke,Yano ^[1] ; Kazuki,Nishimura ^[1] ; Kyosuke,Nishio ^[1] ; Keita,Nakamori ^[1] ; Kosuke,Iwatani ^[2] ; Shutaro,Yamamoto ^[2] ; Fumihiko,Urabe ^[2] ; Keiichiro,Mori ^[2] ; Takafumi,Yanagisawa ^[2] ; Shunsuke,Tsuduki ^[2] ; Kiyoshi,Takahara ^[4] ; Teruo,Inamoto ^[1] ; Jun,Miki ^[2] ; Takahiro,Kimura ^[2] ; Yoshio,Ohno ^[3] ; Ryoichi,Shiroki ^[4] ; Shin,Egawa ^[2] ; Haruhito,Azuma ^[1]

作者单位： Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan. ^[1] Department of Urology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan. ^[2] Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan. ^[3] Department of Urology, Fujita-Health University School of Medicine, Toyoake City, Aichi, Japan. ^[4]

关键词 objective response overall survival pembrolizumab platinum-refractory re-challenging chemotherapy urothelial carcinoma